|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||6.47 - 6.47|
|52 Week Range||6.47 - 6.47|
|Beta (5Y Monthly)||0.05|
|PE Ratio (TTM)||6.66|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
(Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the
Brazil's Butantan biomedical institute is in talks to sell a locally manufactured COVID-19 vaccine developed by China's Sinovac to other countries in South America and Africa, as the federal government has not ordered more of the shots. Butantan Director Dimas Covas said on Wednesday that the institute also has contracts to supply the vaccine directly to Brazilian states. Butantan is currently producing the shot developed by Sinovac Biotech Ltd in the Sao Paulo state using inputs imported from China, but it aims to complete a factory for 100% local production by early next year.
China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa to supply the African continent with shots against a range of diseases, the chief executive of its local partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents.